Abstract Poverty relief can address an immediate need, but lasting poverty reduction requires interventions that change what happens next. This article examines why education, particularly entrepreneurial education combined with financial literacy and access to capital, can generate stronger long-term social returns than short-term assistance alone. Drawing on global
Abstract Carbon markets have a data problem: when emissions reductions are measured through periodic site visits, manual audits, and self-reported information, even a legitimate carbon credit can be difficult to verify with confidence. This article examines the data infrastructure behind Qritos, a Cognigence Green Earth portfolio company, and how
Inside Vytal Health Solutions, A Cognigence Portfolio Spotlight Abstract Healthcare quality should not depend on a patient's zip code. This article examines the growing access gap facing rural, low-income, uninsured, and underserved communities, where hospital closures, provider shortages, limited broadband, and fragmented telehealth systems continue to delay
Abstract Prehospital care is one of the most information-starved environments in healthcare, where paramedics and emergency teams often make critical decisions without access to complete patient histories, encounter records, behavioral health information, or real-time hospital capacity. This article examines how fragmented communication between first responders, hospitals, and community
Abstract When the economy feels uncertain, charitable giving often becomes one of the first things people reconsider. Yet 2026 is precisely when philanthropy matters most. As government funding declines and donor expectations rise, every charitable dollar must work harder and deliver measurable results. This article explores why strategic giving is
Abstract Donor-advised funds have quietly become one of the most powerful forces in modern philanthropy, placing more than $326 billion in charitable capital under the control of donors seeking greater flexibility, tax efficiency, and long-term impact. This article examines the rapid rise of DAFs and the structural shifts
Educational Content
Venture philanthropy is not just a philosophy. It is a practice and a practice only means something when you can point to the specific decisions it produces. At Cognigence, our impact investing model begins with a rigorous investment thesis: identify companies at the intersection of technology, healthcare and environmental impact
Abstract Despite nearly $600 billion in annual charitable giving, global economic inequality remains deeply entrenched because traditional philanthropy is largely designed to relieve symptoms rather than fund long-term structural change. This article examines how aid-based giving models often fail due to short funding cycles, weak accountability frameworks, and
Abstract Cancer research is entering a critical funding crisis at the exact moment scientific breakthroughs are becoming most possible. This article examines how shrinking federal research budgets, collapsing grant approval rates and the growing “Valley of Death” between laboratory discovery and clinical trials are preventing promising cancer innovations from reaching
Abstract As global crises become increasingly interconnected, the question facing donors in 2026 is no longer whether to give, but where philanthropic capital can generate the greatest measurable impact. This article examines six of the world’s highest-leverage cause areas, including MedTech, cancer research, diabetes prevention, autoimmune disease research,
Abstract Traditional philanthropy is no longer meeting the expectations of modern donors. This article explores the major shift happening across charitable giving in 2026 as donors increasingly move away from opaque, trust-based donation models toward data-driven, impact-focused philanthropy. Drawing on industry research, donor behavior trends, and the
Abstract Despite decades of scientific advancement, the majority of global disease burden continues to receive only a fraction of worldwide medical research funding due to market-driven pharmaceutical incentives and shrinking public research budgets. This article examines the widening “10/90 gap” in global healthcare, where diseases affecting billions of